Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio

Abstract

p21WAF1 appears to be a major determinant of the cell fate in response to anticancer therapy. It was shown previously that HCT116 human colon cancer cells growing in vitro enter a stable arrest upon DNA damage, whereas cells with a defective p21WAF1 response undergo apoptosis. Here we report that the enhanced sensitivity of HCT116/p21-/- cells to chemotherapeutic drug-induced apoptosis correlates with an increased expression of p53 and a modification of their Bax/Bcl-2 ratio in favor of the pro-apoptotic protein Bax. Treatment of HCT116/p21-/- cells with daunomycin resulted in a reduction of the mitochondrial membrane potential and in activation of caspase-9, whereas no such changes were observed in HCT116/p21+/+ cells, providing evidence that p21WAF1 exerts an antagonistic effect on the mitochondrial pathway of apoptosis. Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-α reduced the sensitivity of HCT116/p21-/- cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21+/+ cells. Enhancement of p53 expression after disruption of p21WAF1 resulted from a stabilization of p53, which correlated with an increased expression of the tumor suppressor p14ARF, an inhibitor of the ubiquitin ligase activity of Mdm2. In accordance with the role of p14ARF in p53 stabilization, overexpression of p14ARF in HCT116/p21+/+ cells resulted in a strong increase in p53 activity. Our results identify a novel mechanism for the anti-apoptotic effect of p21WAF1 consisting in maintenance of mitochondrial homeostasis that occurs in consequence of a negative control of p14ARF expression.